2480 Stock Chart & Stats
HK$22.98
-HK$0.40(-1.87%)
At close: 4:00 PM EST
HK$22.98
-HK$0.40(-1.87%)
Day’s Range― - ―
52-Week RangeHK$12.00 - HK$28.00
Previous CloseN/A
Volume1.00K
Average Volume (3M)11.30K
Market Cap
HK$2.79B
Enterprise ValueHK$4.60B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.19
Next Earnings
Aug 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding202,449,040
10 Day Avg. Volume3,820
30 Day Avg. Volume11,300
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.63
Revenue Forecast (FY)HK$439.00M
Beijing Luzhu Biotechnology Co., Ltd. Class H News
2480 FAQ
What was Beijing Luzhu Biotechnology Co., Ltd. Class H’s price range in the past 12 months?
Beijing Luzhu Biotechnology Co., Ltd. Class H lowest stock price was HK$12.00 and its highest was HK$28.00 in the past 12 months.
What is Beijing Luzhu Biotechnology Co., Ltd. Class H’s market cap?
Beijing Luzhu Biotechnology Co., Ltd. Class H’s market cap is HK$2.79B.
When is Beijing Luzhu Biotechnology Co., Ltd. Class H’s upcoming earnings report date?
Beijing Luzhu Biotechnology Co., Ltd. Class H’s upcoming earnings report date is Aug 25, 2026 which is in 17 days.
How were Beijing Luzhu Biotechnology Co., Ltd. Class H’s earnings last quarter?
Beijing Luzhu Biotechnology Co., Ltd. Class H released its earnings results on Mar 18, 2026. The company reported -HK$0.401 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.401.
Is Beijing Luzhu Biotechnology Co., Ltd. Class H overvalued?
According to Wall Street analysts Beijing Luzhu Biotechnology Co., Ltd. Class H’s price is currently Overvalued.
Does Beijing Luzhu Biotechnology Co., Ltd. Class H pay dividends?
Beijing Luzhu Biotechnology Co., Ltd. Class H does not currently pay dividends.
What is Beijing Luzhu Biotechnology Co., Ltd. Class H’s EPS estimate?
Beijing Luzhu Biotechnology Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beijing Luzhu Biotechnology Co., Ltd. Class H have?
Beijing Luzhu Biotechnology Co., Ltd. Class H has 202,449,040 shares outstanding.
What happened to Beijing Luzhu Biotechnology Co., Ltd. Class H’s price movement after its last earnings report?
Beijing Luzhu Biotechnology Co., Ltd. Class H reported an EPS of -HK$0.401 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.783%.
Which hedge fund is a major shareholder of Beijing Luzhu Biotechnology Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2480
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Beijing Luzhu Biotechnology Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
1.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.58%
Trailing 12-Months
Company Description
Beijing Luzhu Biotechnology Co., Ltd. Class H
Beijing Luzhu Biotechnology Co., Ltd., a biotechnology company, develops human vaccines and therapeutic biologics to prevent and control infectious diseases, and to treat cancer and autoimmune diseases in Mainland China. The company is developing LZ901, a recombinant herpes zoster vaccine for which a biologics license application (BLA) has been submitted; K3, a recombinant human anti-tumor necrosis factor-alpha monoclonal antibody injection that has completed a Phase 1 clinical trial for the treatment of autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis; and K193, a bispecific antibody injection in a Phase 1 clinical trial for the treatment of B cell leukemia and lymphoma. Its preclinical-stage product candidates comprise a recombinant varicella vaccine for the prevention of varicella in children; a recombinant syncytial virus (RSV) vaccine for RSV-induced lower respiratory tract disease; a recombinant HSV-1 vaccine that targets oral herpes or cold sores; a recombinant HSV-2 vaccine that targets genital herpes; K333, a bispecific antibody injection product for the treatment of myeloid leukemia; and K1932, a bispecific antibody to treat b cell lymphoma. In addition, the company offers immunoreagents, such as Group A meningococcal polysaccharide IgG, Group C meningococcal polysaccharide IgG, Group Y meningococcal polysaccharide IgG, Group W135 meningococcal polysaccharide IgG, and Haemophilus influenzae Type B polysaccharide IgG antibody detection kits; varicella-zoster virus antibody ELISA testing kits; and varicella-zoster virus antigen slides. Beijing Luzhu Biotechnology Co., Ltd. was incorporated in 2001 and is headquartered in Beijing, China.
Technical Analysis
Genor Biopharma Holdings Limited
―
Jacobio Pharmaceuticals Group Co., Ltd.
―
Shandong Boan Biotechnology Company., Limited. Class H
―
Qyuns Therapeutics Co., Ltd. Class H
―
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H
―